Weekly Recap | PHARMARON -4.42%, most brokers rate it buyWeekly Review·Nov 14, 2026 at 05:34 AM03759-3.45%
G Sachs: Strong 3Q Orders for China's CRO and CDMO Firms Enhance Visibility for 2027AASTOCKS News·Nov 12, 2026 at 07:05 AM02359-1.50%03347-4.44%
Weekly Recap | PHARMARON +7.13%, most brokers rate it buyWeekly Review·Nov 7, 2026 at 06:11 AM03759-3.45%
JPM: China's CDMO Sector Enters New Development Phase; Initiates Overweight on PHARMARON and ASYMCHEM H ShrsAASTOCKS News·Nov 6, 2026 at 07:03 AM03759-3.45%06821-4.87%
Morgan Stanley Sticks to Their Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)Tip Ranks·Nov 5, 2026 at 12:27 AM03759-3.45%300759-1.20%
BOCOM International Holdings Company Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)Tip Ranks·Nov 4, 2026 at 07:26 AM03759-3.45%
Pharmaron climbs 6% as Q3 profit rises 13% on order growthMarket Movers·Oct 30, 2026 at 05:01 AM03759-3.45%
PHARMARON 9M Net Profit Up 9.31% YoY to RMB1.247BAASTOCKS News·Oct 28, 2026 at 01:38 AM03759-3.45%300759-1.20%
Pharmaron Renews Three-Year Research Services Agreement With Newbay TechnologyPUBT·Oct 27, 2026 at 11:13 AM03759-3.45%
HSBC Research: US COINS Act Proposes Curbs on Investment in China's Biotech Sector, but BD Deals UnaffectedAASTOCKS News·Oct 26, 2026 at 08:20 AM01801-2.68%02162-1.68%